Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees

Abstract

Objective The primary objective was to estimate the initiation and adherence rates of 17 α-hydroxyprogesterone caproate (17OHPC) among eligible mothers in a statewide population-based cohort of Medicaid enrollees. The secondary objectives were to (1) determine the association of maternal sociodemographic and clinical characteristics with 17OHPC utilization and (2) assess the real-world effectiveness of 17OHPC on recurrent preterm birth prevention and admission to neonatal intensive care unit (NICU).

Study Design This is a retrospective cohort study using a linked, longitudinal administrative dataset of birth certificates and medical assistance claims. Medicaid-enrolled mothers in Pennsylvania were included in this study if they had at least one singleton live birth from 2014 to 2016 following at least one spontaneous preterm birth. Maternal Medicaid claims were used to ascertain the use of 17OHPC from various manufacturers, including compounded formulations. Propensity score matching was used to create a covariate balance between 17OHPC treatment and comparison groups.

Results We identified 4,781 Medicaid-covered 17OHPC-eligible pregnancies from 2014 to 2016 in Pennsylvania, 3.4% of all Medicaid-covered singleton live births. The population-based initiation rate was 28.5% among eligible pregnancies. Among initiators, 50% received ≥16 doses as recommended, while 10% received a single dose only. The severity of previous spontaneous preterm birth was the strongest predictor for the initiation and adherence of 17OHPC. In the matched treatment (n = 1,210) and comparison groups (n = 1,210), we found no evidence of 17OHPC effectiveness. The risks of recurrent preterm birth (relative risk [RR] 1.10, 95% confidence interval [CI] 0.97–1.24) and births admitted to NICU (RR 1.00, 95% CI 0.84–1.18) were similar in treated and comparison mothers.

Conclusion The 17OHPC-eligible population represented 3.4% of singleton live births. Less than one-third of eligible mothers initiated treatment. Among initiators, 50% were treatment adherent. We found no difference in the risk of recurrent preterm birth or admission to NICU between treatment and comparison groups.

Key Points

• About 3.4% of singleton live births were eligible for 17OHPC.

• About 30% of eligible mothers initiated treatment.

• We found no association of 17OHPC with recurrent preterm birth.

Keywords

17 α-hydroxyprogesterone caproate - 17P - Medicaid - neonatal intensive care unit - preterm birth - progesterone - recurrent preterm birth - spontaneous preterm birth

Publikationsverlauf

Eingereicht: 03. Dezember 2020

Angenommen: 04. Oktober 2021

Artikel online veröffentlicht:
16. November 2021

• References

• 1 Martin JA, Hamilton BE, Osterman MJK. Births in the United States, 2018; NCHS Data Brief No. 346. 2019 ;(346):7. Accessed December 3, 2020 https://www.cdc.gov/nchs/data/databriefs/db346-h.pdf
• 2 Mazaki-Tovi S, Romero R, Kusanovic JP. et al. Recurrent preterm birth. Semin Perinatol 2007; 31 (03) 142-158
• 3 Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120 (04) 964-973
• 4 Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017; 216 (03) B11-B13
• 5 Meis PJ, Klebanoff M, Thom E. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348 (24) 2379-2385
• 6 The Food and Drug Administration (FDA) Division of Bone, Reproductive, and Urologic Products. FDA Briefing Document NDA 021945 Hydroxyprogesterone Caproate Injection (trade name Makena). 2019 Accessed December 3, 2020 at: https://www.fda.gov/media/132003/download
• 7 Blackwell SC, Gyamfi-Bannerman C, Biggio JR. et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial. Am J Perinatol 2020; 37 (02) 127–136
• 8 Batra P, Hirai A, Selk S, Lee V, Lu M. Appropriate use of progesterone to prevent preterm birth: approaches to measurement for driving improvement. Matern Child Health J 2017; 21 (03) 446-451
• 9 Stringer EM, Vladutiu CJ, Manuck T. et al. 17-hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: a retrospective cohort study. Am J Obstet Gynecol 2016; 215 (01) 105.e1-105.e12
• 10 Orsulak MK, Block-Abraham D, Gee RE. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population. Clin Ther 2015; 37 (04) 727-732
• 11 Dusetzina SB, Tyree S, Meyer A-M, Meyer A, Green L, Carpenter WR. Linking Data for Health Services Research: A Framework and Instructional Guide. 2014 . Doi: AHRQ No.14–EHC033
• 12 Klebanoff MA, Yossef-Salameh L, Latimer C. et al. Development and validation of an algorithm to determine spontaneous versus provider-initiated preterm birth in US vital records. Paediatr Perinat Epidemiol 2016; 30 (02) 134-140
• 13 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371(9606):75–84
• 14 Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010; 25 (01) 1-21
• 15 Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159 (07) 702-706
• 16 VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 2017; 167 (04) 268-274
• 17 Commonwealth of Pennsylvania Department of Health. Resident live births by principal source of payment and age of mother. 2017 ;(c):2013–2017
• 18 Hamilton BE, Martin JA, Osterman MJK, Driscoll AK, Rossen LM. Births: provisional data for 2017. NVSS Vital Stat Rapid Release. 2018; 2 (02) 1-21 Accessed December 3, 2020 at: https://www.cdc.gov/nchs/data/vsrr/report002.pdf
• 19 Petrini JR, Callaghan WM, Klebanoff M. et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005; 105 (02) 267-272
• 20 Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth. Am J Obstet Gynecol 2017; 217 (03) 371.e1-371.e7
• 21 Turitz AL, Bastek JA, Purisch SE, Elovitz MA, Levine LD. Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort. Am J Obstet Gynecol 2016; 214 (04) 536.e1-536.e5
• 22 Boelig RC, Jiang E, Scheidemantle B, Villani M, Berghella V. Utilization of progesterone and cervical length screening for prevention of recurrent preterm birth. J Matern Neonatal Med 2019; 32 (24) 4146-4153
• 23 Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ. 17-alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol 2017; 216 (06) 600.e1-600.e9
• 24 Sourth Carolina Department of Health and Human Services. Medicaid bulletin 15–004 Coverage of Hydroxyprogesterone Injection. Accessed December 3, 2020 at: https://www.scdhhs.gov/press-release/coverage-hydroxyprogesterone-injection
• 25 Iams JD, Applegate MS, Marcotte MP. et al. A state wide progestogen promotion program in Ohio. Obstet Gynecol 2017; 129 (02) 337-346
• 26 Thoma ME, Copen CE, Kirmeyer SE. Short interpregnancy intervals in 2014: differences by maternal demographic characteristics. NCHS Data Brief 2016; 240: 1-8